Literature DB >> 22093225

Peptide nanoparticles for oligonucleotide delivery.

Taavi Lehto1, Kariem Ezzat, Ulo Langel.   

Abstract

In the past two decades, different methods have emerged for intervention with gene expression, which can be generally referred to as gene therapy. Oligonucleotides (ONs) and their analogs form the basis of the molecules that can be used to modulate gene expression. Unfortunately, due to their physicochemical properties, these molecules require assistance in their intracellular delivery. Cell-penetrating peptides (CPPs) are one class of nonviral delivery vectors that, because of their remarkable translocation properties, have been intensely utilized for the delivery of ON-based molecules, both in vitro and in vivo. This chapter concentrates on the applications of CPPs that directly form nanoparticles with different ONs and facilitate their intracellular delivery.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22093225     DOI: 10.1016/B978-0-12-416020-0.00010-3

Source DB:  PubMed          Journal:  Prog Mol Biol Transl Sci        ISSN: 1877-1173            Impact factor:   3.622


  3 in total

1.  An ultra pH-sensitive and aptamer-equipped nanoscale drug-delivery system for selective killing of tumor cells.

Authors:  Nianxi Zhao; Jian You; Zihua Zeng; Chun Li; Youli Zu
Journal:  Small       Date:  2013-04-23       Impact factor: 13.281

Review 2.  Stable RNA nanoparticles as potential new generation drugs for cancer therapy.

Authors:  Yi Shu; Fengmei Pi; Ashwani Sharma; Mehdi Rajabi; Farzin Haque; Dan Shu; Markos Leggas; B Mark Evers; Peixuan Guo
Journal:  Adv Drug Deliv Rev       Date:  2013-11-22       Impact factor: 15.470

3.  Solid formulation of cell-penetrating peptide nanocomplexes with siRNA and their stability in simulated gastric conditions.

Authors:  Kariem Ezzat; Eman M Zaghloul; Samir El Andaloussi; Taavi Lehto; Ramy El-Sayed; Tarek Magdy; C I Edvard Smith; Ulo Langel
Journal:  J Control Release       Date:  2012-06-12       Impact factor: 9.776

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.